Department of System Biology, Center of Molecular Immunology, Havana, Cuba.
Onco Targets Ther. 2013 Jul 24;6:931-42. doi: 10.2147/OTT.S33532. Print 2013.
Nimotuzumab is a humanized monoclonal antibody that binds specifically to human epidermal growth factor receptor, blocking receptor activation. Evidence of its radiosensitizing capacity has been widely evaluated. This article integrates published research findings regarding the role of nimotuzumab in the treatment of high grade glioma in combination with radiotherapy or radiochemotherapy in adult and pediatric populations. First, the mechanisms of action of nimotuzumab and its current applications in clinical trials containing both radiation and chemoradiation therapies are reviewed. Second, a comprehensive explanation of potential mechanisms driving radiosensitization by nimotuzumab in experimental settings is given. Finally, future directions of epidermal growth factor receptor targeting with nimotuzumab in combination with radiation containing regimens, based on its favorable toxicity profile, are proposed. It is hoped that this review may provide further insight into the rational design of new approaches employing nimotuzumab as a useful alternative for the therapeutic management of high grade glioma.
尼莫珠单抗是一种人源化单克隆抗体，特异性结合人表皮生长因子受体，阻断受体激活。其放射增敏能力的证据已得到广泛评估。本文综合了已发表的研究结果，探讨了尼莫珠单抗在成人和儿科人群中联合放疗或放化疗治疗高级别脑胶质瘤中的作用。首先，回顾了尼莫珠单抗的作用机制及其在包含放疗和放化疗的临床试验中的当前应用。其次，全面解释了尼莫珠单抗在实验环境中诱导放射增敏的潜在机制。最后，基于其良好的毒性特征，提出了尼莫珠单抗联合含辐射方案的表皮生长因子受体靶向治疗的未来方向。希望本综述能为合理设计新方法提供进一步的见解，将尼莫珠单抗作为治疗高级别脑胶质瘤的一种有用选择。
